LEGN250117C30000
- 3.82
- 0.000.00%
Legend Biotech Newsroom
Top Midday Decliners
CCTV interprets a more proactive fiscal policy: next year's fiscal funding will be allocated earlier, faster, and in greater amounts.
Next year, a more proactive fiscal policy will be implemented. What measures will the Ministry of Finance take? Where will the fiscal funds be focused? What impact will this have on our lives?
Legend Biotech Announces Employee Transition Agreement
Express News | Legend Biotech Corp: Appointment of Jessie Yeung as Interim CFO
Express News | Legend Biotech Corp: Resignation of Lori Macomber as CFO- SEC Filing
Express News | Legend Biotech Corp : JP Morgan Cuts Target Price to $77 From $80
25 U.S. 'Highest Conviction' Stocks – UBS
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
(LEGN) - Analyzing Legend Biotech's Short Interest
The Central Economic Work Conference was held in Peking, and **** delivered an important speech.
The Central Economic Work Conference was held in Peking, where **** delivered an important speech, Li Qiang gave a summary speech, and ****, ****, Cai Qi, ****, and Li Xi attended the meeting.
Express News | The Central Economic Work Conference states that a moderately loose MMF policy should be implemented, with timely reductions in reserve requirements and interest rates, to maintain ample liquidity.
Express News | Central Economic Work Conference: There will be a more proactive fiscal policy, increasing the fiscal deficit ratio.
Express News | Central Economic Work Conference: Implement a more proactive macro policy, expand domestic demand, promote the integration of technological innovation and industrial innovation development, and stabilize the property and stock markets.
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
Deep Dive Into Legend Biotech Stock: Analyst Perspectives (10 Ratings)
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $65 to $91
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Optimistic Buy Rating for Legend Biotech Driven by Carvykti's Success and Growth Potential
William Blair Sticks to Its Hold Rating for Legend Biotech (LEGN)
Legend Biotech Reports Advancement of Carvykti as 'Leading' Multiple Myeloma Treatment